Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy

Submitted by Anonymous on

Original Article Share on Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI TherapyAuthors: Shun Lu, M.D., Nicolas Girard, M.D., Ph.D., James Chih-Hsin Yang, M.D., Ph.D., Frances A. Shepherd, M.D., Xiaorong Dong, M.D., Ph.D., Surein Arulananda, Ph.D., Giulio Metro, M.D., +26...

Severe cutaneous adverse reaction to aumolertinib plus vebreltinib in an EGFR-mutant NSCLC patient: a case report

Submitted by Anonymous on

BackgroundThe combination of aumolertinib and vebreltinib has emerged as an effective therapeutic strategy for advanced non-small cell lung cancer(NSCLC) har Abstract Background: The combination of aumolertinib and vebreltinib has emerged as an effective therapeutic strategy for advanced non-small cell lung...

Another win for novel drug, this time in EGFR-mutated lung cancer

Submitted by Anonymous on

Izalontamab brengitecan nearly doubled PFS compared with chemotherapy A first-in-class bispecific antibody-drug conjugate (ADC) nearly doubled progression-free survival (PFS) compared with chemotherapy in patients with EGFR -mutated advanced non-small cell lung cancer (NSCLC) who progressed on third-generation EGFR tyrosine kinase...

Multimodal deep learning framework integrating deep radiomics, clinical features, and EGFR Status to predict growth trends of pulmonary ground-glass nodules

Submitted by Anonymous on

AbstractBackground Pulmonary ground-glass nodules (GGNs) are commonly identified in low-dose computed tomography (CT) screenings. However, their indolent growth patterns often require prolonged follow-up to differentiate benign from malignant, presenting significant challenges for clinical decision-making and patient well-being. This study aims...

BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer

Submitted by Anonymous on

--BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced a collaboration with Foundation Medicine, Inc. to develop a companion diagnostic assay for...

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial

Submitted by Anonymous on

--ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today presented potential best-in-class data for enozertinib in first-line NSCLC patients with EGFR atypical mutations at ESMO Congress 2026 and...

ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations

Submitted by Anonymous on

AstraZeneca today announced the US availability of ZEGFROVY ® for the treatment of adults with locally advanced or metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA- approved...

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

Submitted by Anonymous on

--HUTCHMED Limited today announces that further to its announcement on September 3, 2026 and following the completion of customary closing conditions including antitrust regulatory reviews, the exclusive development and license agreement between HUTCHMED Limited and a subsidiary of GSK plc...

Subscribe to Newsfeed